

10/510393

DT04 Rec'd T/PTO 05 OCT 2004

"Express Mail" mailing label number	EL832893655 US
Date of Deposit	10-05-04
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Printed Name	Queen Thomas
Signature	Queen Thomas

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Britta Evers, et al.

For: GROWTH HORMONE SECRETAGOGUES

Docket No.: X-15555

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,



William R. Boudreaux  
Attorney for Applicants  
Registration No. 35,796  
Telephone: 317-276-0755

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

October 4, 2004

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-15555	Serial No
	Applicants Britta Evers, et al.	
	Filing Date	Group

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US 5,663,171	9/2/97	Chen, et al.	
	AB	US 5,652,235	7/29/97	Chen, et al.	
	AC	US 5,492,916	2/20/96	Marriello, et al.	
	AD	US 5,578,593	11/26/96	Chen, et al.	
	AE	US 5,494,919	2/27/96	Marriello, et al.	
	AF	US 5,492,920	2/20/96	Chen, et al.	
	AG	US 5,559,128	9/24/96	Chakravarty, et al.	
	AH	US 5,583,130	12/10/96	Bochis, et al.	
	AI	US 5,773,441	6/30/98	Hipskind, et al.	
	AJ	US 3,711,495	1/16/93	Kulsa, et al.	
	AK	US 3,984,426	10/5/76	Winkelmann, et al.	
	AL	US 5,380,866	1/10/95	Barnett, et al.	
	AM	US 5,242,903	9/7/93	Bender, et al.	
	AN	US 5,401,851	3/28/95	Boyd, et al.	
	AO	US 5,459,156	10/17/95	Muller-Gliemann, et al.	
	AP	US 5,574,167	11/12/96	Jaber	
	AQ	US 5,661,161	8/26/97	Anthony, et al.	
	AR	US 5,700,827	12/23/97	Schnorrenberg, et al.	
	AS	US 5,756,528	5/26/98	Anthony, et al.	
	AT	US 5,798,337	8/25/98	Somers, et al.	

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-15555	Serial No. <b>10/510393</b>
	Applicants Britta Evers, et al.	
	Filing Date	Group

	AU	US 5,721,250	2/24/98	Morriello, et al.	
	AV	US 5,663,146	9/2/97	Bowers, et al.	
	AW	US 6,046,333	4/4/00	Dorziotis, et al.	
	AX	US 5,830,855	11/3/98	Takemoto	
	AY	US 5,206,235	4/27/93	Fisher, et al.	
	AZ	US 6,329,342	12/11/01	Kauffman, et al.	
	AAA	US 6,639,076	10/28/03	Hauser, et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	BA	WO 97/24369 A1	7/10/97	PCT		
	BB	WO 96/38471 A1 /	12/5/96	PCT		
	BC	WO 96/35713 A1 /	11/14/96	PCT		
	BD	WO 97/41878 A1 /	11/13/97	PCT		
	BE	WO 97/34604 A1 /	9/25/97	PCT		
	BF	WO 97/15573 A1 /	5/1/97	PCT		
	BG	EP 0 761219 A1 /	8/14/96	EPO		
	BH	WO 00/12047 A2 /	3/9/00	PCT		
	BI	WO 99 08697 A1 /	2/25/99	PCT		
	BJ	WO 98/16527 A1 /	4/23/98	PCT		
	BK	EP 0 662 481 B1 /	8/12/93	EPO		
	BL	WO 99/08699 A1 /	2/25/99	PCT		

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-15555	Serial No. <b>10/510393</b>
	Applicants Britta Evers, et al.	
	Filing Date	Group

	BM	EP 0 615977 A1 /	9/21/94	EPO		
	BN	WO 00/49037 A1	8/24/00	PCT		
	BO	WO 96/15148	5/23/96	PCT		
	BP	WO 94/13696 A1	6/23/94	PCT		
	BQ	WO 95/11029 A1 /	4/27/95	PCT		
	BR	EP 0 761 220 A1	12/3/97	EP		
	BS	EP 0 761 219 A1 /	12/30/98	PCT		
	BT	WO 98/58948 A1 /	12/30/98	PCT		
	BU	WO 98/18815 /	5/7/98	PCT		
	BV	WO 97/24369 /	7/10/97	PCT		
	BW	WO 94/13696 /	6/23/94	PCT		
	BX	WO 00/49037	8/24/00	PCT		

# NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
	CA	<u>Synthesis of 4-Nitroimidazoles with 1-Substituents Containing Acid, Ester or Phenol Functions, and Radiosensitizing Efficiency of Some of These Compounds</u> , Suwinski, et al., Arch. Pharm., Vol. 325, pp. 317-324 (1992)	
	CB	<u>Synthetic Approaches to the 'Azole' Peptide Mimetics</u> , Gordon, et al., Tetrahedron Letters, Vol. 34, No. 12, pp. 1901-1904 (1993)	
	CC	Chem. Abst. No. 130:209977, Kauffman, et al., <u>Treatment of Congestive Heart Failure with Growth Hormone Secretagogues</u> , Kauffman, et al. application of WO 99/08697, August 19, 1998	
	CD	Chem. Abst. No. 130:182769, Dodge, et al., <u>Preparation of Heterocyclic Peptide Derivatives as Growth Hormone Secretagogues</u> , application of WO 9908699, August 19, 1998	
	CE	<u>New Highly Potent Dipeptide Growth Hormone Secretagogues with Low Molecular Weight</u> : Eur. J. Med. Chem. 35, pp. 599-618 (2000).	
	CF	<u>Growth Hormone Secretagogues Derived from NN703 with Hydrazides as C-terminal</u> : Eur. J. Med. Chem. 35, pp. 487-497 (2000).	

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-15555	Serial No <b>10/510393</b>
	Applicants Britta Evers, et al.	
	Filing Date	Group

	CG	Chem. Abst. No. 119:261758, Uzunov, et al., <u>Some Aspects of the Enantiorecognition of Derivatized Primary Amines on a Pirkle-Type Chiral Stationary Phase Utilizing Tocainide and Mexiletine as Model Compounds</u> , (1993)	
	CH	Chem. Abst. No. 138:221510, Kim et al., <u>Synthesis and Antiinflammatory-Analgesic Activity of Monovalent and Bivalent Aminoantipyridines</u> (2002).	
Examiner Signature	Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.